TY - JOUR
T1 - Primary ovarian insufficiency and human papilloma virus vaccines
T2 - a review of the current evidence
AU - Christianson, Mindy S.
AU - Wodi, Patricia
AU - Talaat, Kawsar
AU - Halsey, Neal
N1 - Funding Information:
N.H. serves on safety review committees for postlicensure safety assessment of HPV vaccine studies sponsored by Merck. The other authors report no conflict of interest.This work was supported by the Clinical Immunization and Safety Assessment (CISA) Project under contract number 200-2012-53664 from the Centers for Disease Control and Prevention (CDC).
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2020/3
Y1 - 2020/3
N2 - Human papilloma virus is the primary causative agent for cervical cancer, and vaccination is the primary means of preventing anogenital cancers caused by human papilloma virus infection. Despite the availability of human papilloma virus vaccines for more than a decade, coverage rates lag behind those for other vaccines. Public concerns regarding safety of human papilloma virus vaccines have been identified as an important barrier to vaccination, including concerns that the human papilloma virus vaccine may cause primary ovarian insufficiency, driven in part by isolated reports of ovarian failure following the human papilloma virus vaccine. We summarize published peer-reviewed literature on human papilloma virus vaccines and primary ovarian insufficiency, reviewing information contained in the case reports and series. Healthcare providers should address any patient concerns about primary ovarian insufficiency and the human papilloma virus vaccine by acknowledging the case reports but noting the lack of association found in a recently published epidemiologic study of approximately 60,000 female individuals. Current evidence is insufficient to suggest or to support a causal relationship between human papilloma virus vaccination and primary ovarian insufficiency.
AB - Human papilloma virus is the primary causative agent for cervical cancer, and vaccination is the primary means of preventing anogenital cancers caused by human papilloma virus infection. Despite the availability of human papilloma virus vaccines for more than a decade, coverage rates lag behind those for other vaccines. Public concerns regarding safety of human papilloma virus vaccines have been identified as an important barrier to vaccination, including concerns that the human papilloma virus vaccine may cause primary ovarian insufficiency, driven in part by isolated reports of ovarian failure following the human papilloma virus vaccine. We summarize published peer-reviewed literature on human papilloma virus vaccines and primary ovarian insufficiency, reviewing information contained in the case reports and series. Healthcare providers should address any patient concerns about primary ovarian insufficiency and the human papilloma virus vaccine by acknowledging the case reports but noting the lack of association found in a recently published epidemiologic study of approximately 60,000 female individuals. Current evidence is insufficient to suggest or to support a causal relationship between human papilloma virus vaccination and primary ovarian insufficiency.
KW - human papilloma virus vaccination
KW - premature ovarian failure
KW - primary ovarian insufficiency
UR - http://www.scopus.com/inward/record.url?scp=85076606113&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076606113&partnerID=8YFLogxK
U2 - 10.1016/j.ajog.2019.08.045
DO - 10.1016/j.ajog.2019.08.045
M3 - Article
C2 - 31479634
AN - SCOPUS:85076606113
SN - 0002-9378
VL - 222
SP - 239
EP - 244
JO - American journal of obstetrics and gynecology
JF - American journal of obstetrics and gynecology
IS - 3
ER -